Kerendia (finerenone) received its initial approval from the U.S. Food and Drug Administration (FDA) on July 8, 2021 [1].
When did Kerendia get approved in Europe?
In the European Union, Kerendia was approved by the European Medicines Agency (EMA) on July 16, 2021 [2].
What is Kerendia used for?
Kerendia is a medication used to treat chronic kidney disease (CKD) associated with type 2 diabetes [1]. It works by reducing inflammation and fibrosis in the kidneys [3].
What is the mechanism of action for Kerendia?
Kerendia is a non-steroidal selective mineralocorticoid receptor antagonist [1]. It blocks the detrimental effects of excess mineralocorticoid receptor stimulation, which can contribute to kidney damage and cardiovascular disease in patients with type 2 diabetes [3].
What are the key clinical trial results for Kerendia?
The FDA approval was based on data from the Phase III FIDELITY program, which included the F-1 and F**-2 studies [1]. These studies demonstrated that finerenone significantly reduced the risk of kidney disease progression and cardiovascular events in patients with CKD and type 2 diabetes [4]. Specifically, it was shown to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), kidney failure, and kidney death, as well as cardiovascular death, non-fatal myocardial infarction, and cardiovascularlessness [4].
What are the side effects of Kerendia?
Common side effects of Kerendia include hyperkalemia (high potassium levels), hypotension (low blood pressure), and diarrhea [1]. Patients taking Kerendia should have their potassium levels monitored regularly [1].
What is the patent expiration timeline for Kerendia?
Information regarding the specific patent expiration dates for Kerendia is available through resources like DrugPatentWatch.com [5]. Patent exclusivity can be complex and may involve multiple patents covering different aspects of the drug, formulation, or use [5].
Can generic versions of Kerendia be developed?
Once patents and other exclusivities expire, generic manufacturers may be able to develop and market generic versions of Kerendia [5]. The development and approval process for generics involves demonstrating bioequivalence to the brand-name drug [5].
Who manufactures Kerendia?
Kerendia is manufactured by Bayer [1].
How does Kerendia compare to other CKD treatments?
Kerendia offers a novel approach for patients with CKD and type 2 diabetes by targeting the mineralocorticoid receptor pathway, distinct from traditional treatments like ACE inhibitors and ARBs [3][4]. Its demonstrated ability to reduce both kidney and cardiovascular events makes it a significant addition to the treatment landscape for this patient population [4].
What are the regulatory considerations for Kerendia?
The FDA and EMA approvals signify that regulatory agencies have reviewed the safety and efficacy data and determined that the benefits of Kerendia outweigh its risks for the approved indication [1][2]. Ongoing post-market surveillance monitors the drug's performance in the real world [1].
What are patient concerns regarding Kerendia?
Patients may have concerns about managing potential side effects like hyperkalemia and hypotension, and the need for regular monitoring of potassium levels [1]. Understanding the drug's mechanism and benefits in the context of their specific condition is also important for patients [3].
Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-kerendia-finerenone-reduce-risk-kidney-and-cardiovascular-outcomes-adults-type-2-diabetes
[2] https://www.ema.europa.eu/en/medicines/human/EPAR/kerendia
[3] https://www.bayer.com/en/news/press-releases/bayer-announces-us-food-and-drug-administration-fda-approval-kerendia-finerenone-reduce-risk-kidney-and-cardiovascular-outcomes-adults-type-2-diabetes
[4] https://www.nejm.org/doi/full/10.1056/NEJMoa2205530
[5] https://drugpatentwatch.com/